Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis

Videos

SPONSORED CONTENT: Morie Gertz, MD, reviews data on the use of birtamimab plus standard-of-care anti-plasma cell chemotherapy in patients with light-chain amyloidosis, which was investigated in the phase 3 randomized, placebo-controlled VITAL trial.

Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis: The Phase 3 Randomized, Placebo-Controlled VITAL Trial

Morie Gertz, MD, the chair of the Department of Medicine at the Mayo Clinic, discusses expanding treatment options for myeloma.

There are a number of new agents that are being used for the management of myeloma, says Gertz.  Daratumumab, a fully human IgG1k monoclonal antibody that targets CD38, has demonstrated promising activity as monotherapy in patients with relapsed/refractory multiple myeloma.

Carfilzomib, lenalidomide, and dexamethasone have been shown to improve progression-free survival. Panobinostat, a deacetylase (DAC) inhibitor is also being used in new ways to treat myeloma.

Morie Gertz, MD

Articles

Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis: The Phase 3 Randomized, Placebo-Controlled VITAL Trial

Dr. Gertz on Expanding Treatment Options for Myeloma